---
title: "Biogen: LEQEMBI IQLIK Autoinjector Available In U.S. For Early Alzheimer's"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296787337.md"
description: "Eisai and Biogen announced the U.S. availability of LEQEMBI IQLIK, a once-weekly subcutaneous autoinjector for early Alzheimer's disease. This marks the first anti-amyloid treatment allowing at-home dosing. Following the announcement, Biogen shares rose 0.38% in pre-market trading to $217.60."
datetime: "2026-08-24T12:23:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296787337.md)
  - [en](https://longbridge.com/en/news/296787337.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296787337.md)
generator: "portal-rs"
---

# Biogen: LEQEMBI IQLIK Autoinjector Available In U.S. For Early Alzheimer's

Add  as your preferred news source on Google

 Add Now

Eisai Co. (4523.T,EII.SG) and Biogen (BIIB) announced that once weekly lecanemab-irmb subcutaneous injection - LEQEMBI IQLIK - is now available in the U.S. for initiation therapy for early Alzheimer's disease in adults with mild cognitive impairment or mild dementia due to AD, collectively referred to as early AD. LEQEMBI IQLIK is administered via an autoinjector. 

LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance. The companies will provide a range of resources to help patients, care partners, healthcare providers, health systems and pharmacies successfully implement and use LEQEMBI IQLIK.

In pre-market trading on NasdaqGS, Biogen shares are up 0.38 percent to $217.60.

For More Such Health News, visit rttnews.com. 

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [4523.JP](https://longbridge.com/en/quote/4523.JP.md)

## Related News & Research

- [4,582 Shares in Biogen Inc. $BIIB Purchased by EFG International AG](https://longbridge.com/en/news/297145391.md)
- [Biogen platforms lupus patient advocate in social media push](https://longbridge.com/en/news/297335137.md)
- [Biogen CEO Viehbacher to speak at Morgan Stanley Global Healthcare Conference](https://longbridge.com/en/news/297227566.md)
- [LEQEMBI IQLIK(R) (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease](https://longbridge.com/en/news/297222768.md)
- [Biogen: 4-year Data Support Potential Disease-modifying Effects Of Zorevunersen](https://longbridge.com/en/news/297656275.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**